1-3 of 3
Bruce L. Davidson
Close
Sort by
Journal Articles

Healthcare Cost Impact of Continued Anticoagulation Therapy with Rivaroxaban Versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the Einstein Choice Trial Population

Bruce L. Davidson, MD MPH, Philip S. Wells, MD FRCPC, MSc, Martin H. Prins, MD PhD, Jan Beyer-Westendorf, MD, Anthonie WA. Lensing, MD PhD, Lloyd Haskell, MD, Bennett Levitan, MD PhD, François Laliberté, Veronica Ashton, MPH, Yongling Xiao, PhD, Dominique Lejeune, Concetta Crivera, Patrick Lefebvre, MA, Qi Zhao, MPH, Zhong Yuan, MD PhD, Jeff Schein, Paolo Prandoni, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 218.
https://doi.org/10.1182/blood.V130.Suppl_1.218.218
Published: 2017
Journal Articles

A Phase II Randomized, Double-Blind, Eight-Arm, Parallel-Group, Dose-Response Study of Apixaban, a New Oral Factor Xa Inhibitor for the Prevention of Deep Vein Thrombosis in Knee Replacement Surgery - On Behalf of the Apixaban Investigators.

Michael R. Lassen, MD, Bruce L. Davidson, MD, Alexander Gallus, MD, Graham Pineo, MD, Jack Ansell, MD, David Deitchman, PhD
Journal: Blood
Blood (2006) 108 (11): 574.
https://doi.org/10.1182/blood.V108.11.574.574
Published: 2006
Journal Articles

Benefit of Fondaparinux in Medical Patients: A Subgroup Analysis.

Alexander T. Cohen, Alexander S. Gallus, Bruce L. Davidson, Michael R. Lassen, Martin H. Prins, Witold Tomkowski, Alexander G.G. Turpie, Jan F.M. Egberts, Anthonie W.A. Lensing
Journal: Blood
Blood (2004) 104 (11): 4079.
https://doi.org/10.1182/blood.V104.11.4079.4079
Published: 2004